Eli Lilly rises about 1% premarket after FDA grants Olomorasib breakthrough therapy designation for pancreatic cancer
Eli Lilly shares rose about 1% in premarket trading after Olomorasib received breakthrough therapy designation from the U.S. Food and Drug Administration for the treatment of pancreatic cancer. The source does not provide a reliable event date separate from the page’s publication timestamp.
Eli Lilly shares rose about 1% in premarket trading after Olomorasib received breakthrough therapy designation from the U.S. Food and Drug Administration for the treatment of pancreatic cancer.
The source does not provide a reliable event date separate from the page’s publication timestamp.
The source does not provide a reliable event date separate from the page’s publication timestamp.